George Abercrombie - Theseus Pharmaceuticals President

THRXDelisted Stock  USD 4.06  0.00  0.00%   

President

Mr. George B. Abercrombie is Senior Vice President Corporationrationrate Partnerships Commercial of the Company. Mr. George B. Abercrombie RPh MBA joined Innoviva Inc. in June 2014. Prior to joining Innoviva Mr. Abercrombie served as the President and Chief Executive Officer of HoffmannLa Roche Inc. from 2001 to 2009 where he was responsible for the US and Canadian business divisions. From 1993 to 2001 Mr. Abercrombie worked at Glaxo and its successor companies including as Senior Vice President of Commercial Operations for Glaxo Wellcome Inc. He is the Chairman of the Board of BioCryst Pharmaceuticals Inc. and also serves as a board member of numerous other healthcarerelated organizations including Project Hope and the North Carolina GlaxoSmithKline Foundation since 2014.
Age 60
Tenure 10 years
Professional MarksMBA
Phone857 400 9491
Webhttps://theseusrx.com
Abercrombie holds an MBA from Harvard Business School and a BS from the University of North Carolina at Chapel Hill, School of Pharmacy.

Theseus Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.1789) % which means that it has lost $0.1789 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2555) %, meaning that it created substantial loss on money invested by shareholders. Theseus Pharmaceuticals' management efficiency ratios could be used to measure how well Theseus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 3.98 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Theseus Pharmaceuticals has a current ratio of 26.99, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Theseus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Theseus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Theseus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Theseus to invest in growth at high rates of return. When we think about Theseus Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Justin PaulTFI International
N/A
Andrea GreenbergSphere Entertainment Co
65
Scott FelensteinNational CineMedia
55
David GranvilleSmithSphere Entertainment Co
57
Christopher BrooksOld Dominion Freight
53
Kevin FreemanOld Dominion Freight
65
David BatesOld Dominion Freight
53
Ross ParrOld Dominion Freight
52
Eric AnsonTFI International
N/A
Sarah HiltyNational CineMedia
47
Patrick CollinsNETGEAR
44
Michael WerdannNETGEAR
56
Larry FuacoTFI International
N/A
Clifford MarksNational CineMedia
56
Tamesa RogersNETGEAR
50
Craig AbrahamsPlaytika Holding Corp
47
Kristen FessTFI International
N/A
Kevin TaitTFI International
N/A
CPA CMATFI International
N/A
Lawrence SnappNational CineMedia
78
John HarringtonTFI International
N/A
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Theseus Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. Theseus Pharmaceuticals (THRX) is traded on NASDAQ Exchange in USA and employs 38 people.

Management Performance

Theseus Pharmaceuticals Leadership Team

Elected by the shareholders, the Theseus Pharmaceuticals' board of directors comprises two types of representatives: Theseus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Theseus. The board's role is to monitor Theseus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Theseus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Theseus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Patrick LePore, Independent Director
DPhil DPHIL, CoFounder Chairman
Nachu Narasimhan, VP Safety
Theodore Witek, Sr. VP of Corporate Partnerships, Clinical and Medical Affairs
WeiSheng Huang, CoFounder Chemistry
Catherine Friedman, Independent Director
James Tyree, Independent Director
Terrence Kearney, Independent Director
Michael Faerm, Chief Bus. Officer and Sr. VP
Barbara Duncan, Independent Director
Paul Pepe, Independent Director
George Abercrombie, Senior Vice President - Corporate Partnerships, Commercial
Timothy Clackson, Pres CEO
Len Rozamus, VP Operations
Eric dEsparbes, CFO and Sr. VP
Bradford Dahms, Chief officer
Alicja Januszewicz, VP Culture
Victor Rivera, VP CoFounder
Benjamin Enerson, VP Affairs
Michael Aguiar, CEO and President and Director
Kristine CPA, VP Controller
William Waltrip, Lead Independent Director
MA DPHIL, CoFounder Chairman
David MD, Chief Officer
William Shakespeare, CoFounder RD

Theseus Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Theseus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Theseus Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Theseus Pharmaceuticals' short interest history, or implied volatility extrapolated from Theseus Pharmaceuticals options trading.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Other Consideration for investing in Theseus Stock

If you are still planning to invest in Theseus Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Theseus Pharmaceuticals' history and understand the potential risks before investing.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Commodity Directory
Find actively traded commodities issued by global exchanges
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities